Cancer Research Antibodies and ELISA Kits: Leading Companies and Market Trends.


Min Read

In this blog:

  • What trends have we picked up on for use of ELISA Kits and Antibodies in cancer research?
  • Which reagent suppliers are growing and succeeding in these markets, supporting scientists in their work?
  • Download data on the top 20 antibody and ELISA kit suppliers in cancer research at the bottom of this blog.

With AACR around the corner, we decided to dig back into our reagent data to better understand life science product use in cancer research. 

In this blog, we share with you our analysis of the cancer research market size, trends and key players for ELISA Kits and research antibodies. We uncover the three dominant leaders for each reagent type, and one supplier who appears in the top three in both markets.

If you’re interested in the ELISA kit and antibody space, are trying to benchmark your performance, spot competitors or identify areas of opportunity, read on…

Oncology ELISA Kits: Market trends, Leading Companies and Growing Players

Overview of the cancer research ELISA kit market

Upon examining our citation data to see how scientists have used ELISA kits in published work, and from which companies they are buying these kits from, we found that the market has witnessed some dynamic changes.

Primarily, we noticed there have been some major shifts in share for the leading companies. Our data suggests that there are over 140 vendors at play in the ELISA Kit market.

With data for over 760k ELISA kits in our complete database, the market is certainly a large and competitive space. So, who should you be paying attention to? 

Which suppliers are leading with the most oncology ELISA kit citations?

Leading the pack, as they are in the global ELISA Kit market across all research areas, are R&D Systems. Their strong market share showcases their support of scientists working in cancer research, with many cases of their kits being cited in published work. 

R&D Systems has experienced a gradual decrease in share throughout the past decade, but still dominates with 27.51% of the market in 2023.

Coming in as the second most cited company were Abcam. Abcam have been increasing their market position over the past decade; impressively growing from a share of 7.59% in 2014 to 21.79% in 2023. 

A graph to show Abcam ELISA kit cancer research market growth, increasing steadily over the years.
Abcam ELISA kit cancer research market growth

In third position by market share were Thermo Scientific. The supplier has consistently maintained this position with around 10% of the market, seeing slight fluctuations in share.

Looking to benchmark your performance, spot competitors and identify areas of opportunity in the ELISA kit market? 

We’ve recently introduced an ELISA Kits Market Insights package, which includes datasets covering countries, companies, top ELISA kit products and research areas, to help you to make data-driven decisions. 

Learn more about the ELISA Kit market insights package and kits data CiteAb produces.

Movers and shakers in the cancer research ELISA kit market

When we looked beyond the top three leaders, we noticed a number of companies with impressive growth trajectories who may be ones to watch.

BioLegend have seen notable increases in market share over the years. Although they are not currently threatening the top three players, they now rank as the 4th most cited supplier in 2023. We recently commented on BioLegend’s growth in the overall ELISA kit market, where they broke into the top five in 2022.

Elabscience have similarly been rising in prominence within the cancer research ELISA Kit market. They have grown from a 0% market share to a 3.13% share within the decade – a trajectory to pay attention to.

We have also found that Elabscience have been growing their share globally, ranking as 6th in 2022. In cancer research they rank in 5th position, showing this research area could be contributing to their success.

Other life science reagent companies that we’ve noticed enter the market within the last decade include: Beyotime Biotechnology, Proteintech, Abclonal and Wuhan Fine Biotech. 

Overall, we found that multiple companies were growing their ELISA kit share in cancer research and the market may get more competitive in years to come.

Oncology Antibody Market: Size, Trends and Leading Companies

Summary of our findings on the oncology research antibody market

Overview of the cancer research antibody market

Our antibody data takes in cancer research monoclonal antibodies, polyclonals and recombinants – giving a comprehensive view of the products in this space. 

So how big is the antibody market in cancer research? Our recent data suggests around 20% of the antibody citations across all of our research areas can be attributed to cancer research, indicating a significant amount of research activity here.

When we dug into who is succeeding in this space, providing research antibodies researchers are using frequently in their work, we found three dominant players, one of which also led in the ELISA kit space. 

Leading cancer research antibody companies

Claiming the top spot by market share is Cell Signaling Technology. CST have maintained a consistent lead throughout the decade, showing sustained support for scientists working in cancer research. Their antibody market share has ranged from 27.98% to 31.85%.

Steadily increasing their market share over the years, Abcam comes in at second position. This growth over the decade certainly makes them ones to watch, taking them from a 10.97% share in 2014 to a 22.2% share in 2023. 

Impressively, Abcam have grown in both the cancer research antibody market and the ELISA Kit market. Abcam are the only supplier featuring in the top three in both of these markets, demonstrating a focus in cancer research.

With the opposite trajectory to Abcam, Santa Cruz Biotechnology comes in as the third most cited company in cancer research. Despite their declining trend, their citation share is certainly still strong here.

Movers and shakers in the oncology antibody market

When we looked outside of the top three, we pinpointed two suppliers that may be ones to watch.

Proteintech and BioLegend have seen substantial growth in citation share from around 1-2% to over 7%, demonstrating increasing use for their antibodies in oncology. Could they challenge the top three in the future?

A graph to show BioLegend's cancer research antibody market share, growing from 2014.
BioLegend cancer research antibody market share

Other companies increasing their share were Abclonal and BioXCell, ranking in 9th and 11th in 2023 respectively. We also found that Servicebio and Affinity Biosciences have entered the market in the last decade – growing their presence from a handful of citations to now featuring in the top 20, marking them as an established source for cancer research antibodies. 

Overall, if companies such as the ones mentioned here continue to grow, we may expect to see some challenges to the top three in the future.

Download the ELISA kit and antibody market data

Data used in this analysis is drawn from our Kits & Assays and Research Antibodies Databases. 

Our ELISA kits data covers over 760k ELISA kits for 142 suppliers worldwide, and our antibody data ~7 million antibodies from over 300 suppliers. We collect this information from the scientific literature using a unique combination of AI-driven text mining and extensive human reviewing. 

To learn more about our data and how you can licence it for unlimited internal use, get in touch with the team! 

Below, simply fill in the form to receive data on the top 20 ELISA kit and Antibody Suppliers in cancer research straight to your inbox so you can dig into the data yourself!

  • Rhys B and the CiteAb team

Sign up for data

Something seems to have gone wrong while loading the form.
Drop us a message and we can send you the data directly.

About the author

Join thousands of people who already enjoy the CiteAb newsletter

To keep up to date with the latest developments to our search engine, news from our life science market data analysis and improvements to our citation provision.